- Question
- How do ADHD medications compare, in children and in adults, for benefit and side effects?
- Study design
- Network meta-analysis of double-blind randomised controlled trials.
- Participants
- 133 trials: 14,346 children and adolescents and 10,296 adults.
- What researchers found
- All medications studied reduced symptoms more than placebo in the short term. Balancing benefit and tolerability, methylphenidate was preferred for children and amphetamines for adults as first choices.
- What this DOES mean
- In the short term (around 12 weeks), ADHD medication reliably reduces symptoms for many people.
- What this DOESN’T mean
- It doesn’t tell us about long-term effects, or which medication will suit you. It doesn’t show medication improves everything in daily life.
- Limitations
- Short trials; outcomes mostly symptom ratings; trials often exclude people with other conditions.
- Evidence level
- Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean
- Original source
- Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
What these labels mean